Skip to main content
OpenTrials

Clinical trial condition

Waldenstrom Macroglobulinemia

Explore clinical trials studying Waldenstrom Macroglobulinemia. Study availability and eligibility vary by location and protocol.

107 public trials 23 recruiting studies
Refine in advanced search Browse all conditions

Waldenstrom Macroglobulinemia trial results

Active, Not Recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, Not Recruiting

Loncastuximab Tesirine in WM

NCT05190705

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Fred Hutch Seattle, Washington, United States
View Trial Details
Active, Not Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

NCT04263480

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Uniklinikum Salzburg Salzburg, Austria
  • Medizinische Universität Wien Vienna, Austria
  • Vivantes Klinikum am Urban Berlin, Germany
  • Ev. Diakoniekrankenhaus Bremen, Germany
View all 17 locations
View Trial Details
Active, Not Recruiting

Ibrutinib + Venetoclax in Untreated WM

NCT04273139

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details
Active, Not Recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details

Related conditions